Canada Markets close in 5 hrs 21 mins

Advanced Proteome Therapeutics Corporation (APC.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.20000.0000 (0.00%)
As of 03:16PM EST. Market open.
Full screen
Previous Close0.2000
Open0.1850
Bid0.2000 x 0
Ask0.2000 x 0
Day's Range0.1850 - 0.2000
52 Week Range0.1200 - 0.5100
Volume22,500
Avg. Volume25,840
Market Cap7.55M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Advanced Proteome Therapeutics Expands Operations

    Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is expanding operations with a new hire and additional lab space.APTI is pleased to report that it has hired an organic chemist and acquired lab space for mammalian cell culture in the Boston University BioSquare facility. The expansion is part of

  • Newsfile

    Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI's site-selective c

  • Newsfile

    Advanced Proteome Therapeutics Provides Update on COVID Program

    Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.As previously announced, APTI's scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and pre